A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis

NCT05247216 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Hemay007 800 mg QD group
DRUG: Hemay007 1200 mg QD group
DRUG: Hemay007 600 mg QD group
DRUG: Hemay007 placebo group

Sponsor

Tianjin Hemay Pharmaceutical Co., Ltd